MA31701B1 - Depsipeptides cycliques - Google Patents

Depsipeptides cycliques

Info

Publication number
MA31701B1
MA31701B1 MA32690A MA32690A MA31701B1 MA 31701 B1 MA31701 B1 MA 31701B1 MA 32690 A MA32690 A MA 32690A MA 32690 A MA32690 A MA 32690A MA 31701 B1 MA31701 B1 MA 31701B1
Authority
MA
Morocco
Prior art keywords
debsy
league
peptide
kallikrein
inhibitors
Prior art date
Application number
MA32690A
Other languages
Arabic (ar)
English (en)
Inventor
Philipp Krastel
Brigitta-Maria Liechty
Josef Gottfried Meingassner
Esther Schmitt
Erwin Paul Schreiner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38805728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31701(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31701B1 publication Critical patent/MA31701B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention porte sur des dépsipeptides cycliques, ou des dérivés de ceux-ci, ayant la structure représentée par la formule (i), et sur des utilisations de ceux-ci, par exemple en tant qu'inhibiteurs de la kallikréine 7 et de la neutrophile élastase humaine
MA32690A 2007-08-17 2010-03-12 Depsipeptides cycliques MA31701B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114507 2007-08-17
PCT/EP2008/060689 WO2009024527A1 (fr) 2007-08-17 2008-08-14 Dépsipeptides cycliques

Publications (1)

Publication Number Publication Date
MA31701B1 true MA31701B1 (fr) 2010-09-01

Family

ID=38805728

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32690A MA31701B1 (fr) 2007-08-17 2010-03-12 Depsipeptides cycliques

Country Status (30)

Country Link
US (2) US8178650B2 (fr)
EP (1) EP2183273B1 (fr)
JP (1) JP5520824B2 (fr)
KR (2) KR20120123579A (fr)
CN (1) CN103298827B (fr)
AR (1) AR068343A1 (fr)
AU (1) AU2008290567B2 (fr)
BR (1) BRPI0815547B8 (fr)
CA (1) CA2696570C (fr)
CL (1) CL2008002394A1 (fr)
CO (1) CO6260099A2 (fr)
CR (1) CR11251A (fr)
CU (2) CU23943B1 (fr)
EA (1) EA017735B1 (fr)
EC (1) ECSP109968A (fr)
ES (1) ES2632392T3 (fr)
GT (1) GT201000037A (fr)
MA (1) MA31701B1 (fr)
MX (1) MX2010001849A (fr)
MY (1) MY151973A (fr)
NZ (1) NZ583284A (fr)
PE (2) PE20141199A1 (fr)
PL (1) PL2183273T3 (fr)
PT (1) PT2183273T (fr)
SV (1) SV2010003485A (fr)
TN (1) TN2010000074A1 (fr)
TW (1) TW200922613A (fr)
UA (1) UA98658C2 (fr)
WO (1) WO2009024527A1 (fr)
ZA (1) ZA201000776B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5401459B2 (ja) 2007-08-17 2014-01-29 ノバルティス アーゲー カリクレイン７を阻害するための環状デプシペプチドの使用
MX2010001849A (es) 2007-08-17 2010-03-10 Novartis Ag Depsipeptidos ciclicos.
EP2396344A2 (fr) * 2009-02-13 2011-12-21 Novartis AG Molécule d'acide nucléique d'un agrégat biosynthétique codant pour des synthases peptidiques non ribosomales et leurs utilisations
US8680054B2 (en) * 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
AR086168A1 (es) * 2011-04-20 2013-11-27 Novartis Ag Procesos para la elaboracion de depsipeptidos macrociclicos e intermediarios
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9067978B2 (en) * 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
EP3097084B1 (fr) 2014-01-23 2020-09-30 Sixera Pharma AB Nouveaux inhibiteurs de la kallikréine 7
WO2015114144A1 (fr) * 2014-02-03 2015-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques de traitement du syndrôme de netherton
WO2015155676A1 (fr) 2014-04-08 2015-10-15 Novartis Ag Procédés basés sur de l'acétal d'aldéhyde pour la fabrication de depsipeptides macrocycliques et nouveaux intermédiaires associés
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
KR101729848B1 (ko) 2015-06-30 2017-04-24 영남대학교 산학협력단 신규한 해양 바실러스속 균주, 이로부터 분리한 화합물 및 상기 화합물의 약제학적 용도
CN106518868B (zh) * 2015-11-04 2018-02-23 衡阳师范学院 激肽释放酶7小分子抑制剂及其制备方法、用途
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
WO2020018888A1 (fr) 2018-07-20 2020-01-23 The Board Of Regents Of The University Of Oklahoma Peptides antimicrobiens et méthodes d'utilisation
US12312414B2 (en) 2019-09-18 2025-05-27 Genentech, Inc. Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043252C2 (de) 1980-11-15 1982-12-02 Degussa Ag, 6000 Frankfurt Cyclische Acetale von N-Acylglutaminsäure -γ- semialdehyden, Verfahren zu deren Herstellung und ihre Verwendung
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE4421113A1 (de) * 1994-06-16 1995-12-21 Biotechnolog Forschung Gmbh Chondramide, Gewinnungsverfahren, Mittel mit Chondramiden und Mischkultur zur Chondramid-Gewinnung
DE19828043A1 (de) 1998-06-24 1999-12-30 Bayer Ag Ektoparasitizide Mittel
JP2000154198A (ja) 1998-11-20 2000-06-06 Nisshin Flour Milling Co Ltd 環状デプシペプチドの固相合成方法及びその中間体
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
US20040110228A1 (en) 2002-04-01 2004-06-10 Mcalpine Shelli R. Combinatorial organic synthesis of unique biologically active compounds
US7872052B2 (en) 2003-06-06 2011-01-18 Arexis Ab Use of heterocyclic compounds as SCCE inhibitors
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005075667A1 (fr) * 2004-02-03 2005-08-18 Bayer Healthcare Ag Methodes de diagnostic et de traitement de maladies associees a la kallikreine 7 (klk7)
US20090186042A1 (en) * 2006-02-27 2009-07-23 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
MX2010001849A (es) 2007-08-17 2010-03-10 Novartis Ag Depsipeptidos ciclicos.
JP5401459B2 (ja) * 2007-08-17 2014-01-29 ノバルティス アーゲー カリクレイン７を阻害するための環状デプシペプチドの使用
US20110112121A1 (en) 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
KR101004362B1 (ko) 2010-03-19 2010-12-28 가톨릭대학교 산학협력단 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제
US20120064136A1 (en) 2010-09-10 2012-03-15 Nanobio Corporation Anti-aging and wrinkle treatment methods using nanoemulsion compositions
WO2012035468A2 (fr) 2010-09-14 2012-03-22 Trima - Israel Pharmaceutical Products Maabarot Ltd. Composition topique moussante
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
JP5943258B2 (ja) 2011-01-24 2016-07-05 アンテリオス， インコーポレイテッド ナノ粒子組成物、その製剤およびその使用
TR201905477T4 (tr) 2011-01-24 2019-05-21 Anterios Inc Nano-parçacık bileşimler.
AR086168A1 (es) 2011-04-20 2013-11-27 Novartis Ag Procesos para la elaboracion de depsipeptidos macrociclicos e intermediarios
US8680054B2 (en) 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates

Also Published As

Publication number Publication date
CL2008002394A1 (es) 2009-05-15
KR20100044893A (ko) 2010-04-30
KR101227231B1 (ko) 2013-01-28
ES2632392T3 (es) 2017-09-12
WO2009024527A1 (fr) 2009-02-26
CU20100032A7 (es) 2011-10-05
UA98658C2 (uk) 2012-06-11
PE20091007A1 (es) 2009-08-14
BRPI0815547A2 (pt) 2015-02-10
SV2010003485A (es) 2011-03-23
MY151973A (en) 2014-07-31
AU2008290567A1 (en) 2009-02-26
TW200922613A (en) 2009-06-01
PE20141199A1 (es) 2014-09-24
CR11251A (es) 2010-03-08
AR068343A1 (es) 2009-11-11
JP2010536731A (ja) 2010-12-02
KR20120123579A (ko) 2012-11-08
CU23943B1 (es) 2013-09-27
ZA201000776B (en) 2010-10-27
CN103298827B (zh) 2017-05-31
CN103298827A (zh) 2013-09-11
EP2183273A1 (fr) 2010-05-12
NZ583284A (en) 2012-04-27
CU20130063A7 (es) 2013-06-28
US9127044B2 (en) 2015-09-08
BRPI0815547B1 (pt) 2020-09-15
GT201000037A (es) 2012-04-30
AU2008290567B2 (en) 2011-05-12
CO6260099A2 (es) 2011-03-22
CA2696570A1 (fr) 2009-02-26
EP2183273B1 (fr) 2017-04-05
EA201000329A1 (ru) 2010-08-30
CA2696570C (fr) 2020-12-29
EA017735B1 (ru) 2013-02-28
US20090156472A1 (en) 2009-06-18
BRPI0815547B8 (pt) 2021-05-25
PL2183273T3 (pl) 2017-09-29
US8178650B2 (en) 2012-05-15
TN2010000074A1 (en) 2011-09-26
US20120196790A1 (en) 2012-08-02
ECSP109968A (es) 2010-03-31
PT2183273T (pt) 2017-05-22
JP5520824B2 (ja) 2014-06-11
MX2010001849A (es) 2010-03-10

Similar Documents

Publication Publication Date Title
EA201000329A1 (ru) Циклические депсипептиды
CY1113989T1 (el) Ρυθμιστες 2,3-διοξυγενασης ινδολοαμινης και μεθοδοι χρησης αυτων
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA33492B1 (fr) Inhibiteurs de bace
MA34916B1 (fr) Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
MX384206B (es) Formulaciones de inhibidores de dpp iv
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
MA29757B1 (fr) Peptides macrocycliques en tant qu'inhibiteurs de la protease ns3 du vhc
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
MA30198B1 (fr) Inhibiteurs de la protease ns3 du vhc
EA200802050A1 (ru) Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
EA200801997A1 (ru) Новые соединения
EA200701799A1 (ru) Транс-каротиноиды, синтез указанных каротиноидов, получение композиций и их применение
EA200870515A1 (ru) Моноциклические гетероарильные соединения
EP2257161A4 (fr) Inhibiteurs de l'ahcy hydrolase destinés au traitement de l'hyper-homocystéinémie
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
MY150745A (en) Isoserine derivatives for use as coagulation factor ixa inhibitors
ATE474834T1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
ATE474574T1 (de) Imidazoazephinonverbindungen
NO20080839L (no) Isotopsubstituerte protonpumpeinhibitorer
EA201201550A1 (ru) Производные альфа-кетоамидов в качестве ингибиторов цистеинпротеаз
MA31252B1 (fr) Macrolides a base d'erythromycine
TN2012000166A1 (fr) NOUVEAUX DERIVES (HETEROCYCLE-TETRAHYDRO-PYRIDINE)-(PIPERAZINYL)-1-ALCANONE ET (HETEROCYCLE-DIHYDRO-PYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75